harpagoside
Harpagoside is an anti-inflammatory small molecule natural product originally isolated from the Harpagophytum procumbens (Devil's Claw) root, but can be isolated from other plants such as Crophularia ningpoensis Hemsl (Figwort). Treatment of HepG2 cells with Harpagoside demonstrated suppression of NF-κB nuclear translocation and degradation of IκB-α, blocking NF-κB activation. Multiple anti-inflammatory cellular effects were correlated with this blockade, as Harpagoside was observed to inhibit the expression of inflammation-mediating enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and to reduce lipopolysaccharide-induced mRNA levels. The suppression of NF-κB activation is indicated as the mechanism beneath the anti-inflammatory effects of Harpagoside. Harpagoside is widely used as a folk remedy to treat rheumatic complaints. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jan 25, 2023 (NCT05925725)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
- Cyclooxygenase-1INHIBITOR
PTGS1 inhibitor
Chemistry & pharmacology
SMILES
C[C@@]1(C[C@@H](O)[C@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)\C=C\C4=CC=CC=C4- Mol. weight
- 494.4884 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS8KGS1DC5ZU ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05925725 | Phase 4 | Jan 25, 2023 | Polyclinic of the Hospitaller Brothers of St. John of God, Budapest |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Polyclinic of the Hospitaller Brothers of St. John of God, Budapest | Academic/Hospital | 1 | 1 | 1 | 2023 |